You are viewing: France Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The France Nuclear Medicine Market was valued at $413.8 Million in 2025 and projected to reach to $873.6 Million by 2030, representing a compound annual growth rate of 16.1%. France's nuclear medicine market is positioned for exceptional growth through 2030, driven by technological advancements, increased healthcare spending, and rising demand for precision diagnostics and targeted therapies.

France Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Nuclear Medicine Market Trends and Insights

  • This represents a compound annual growth rate of 16.1%, significantly outpacing global trends.
  • France's advanced healthcare infrastructure, coupled with increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures, is driving market expansion across oncology, cardiology, and neurology applications. The French nuclear medicine sector benefits from strong government healthcare investment and a well-established regulatory framework that supports innovation.
  • France's aging population and rising prevalence of chronic diseases are accelerating demand for nuclear imaging and targeted radiotherapy solutions.
  • Between 2025 and 2030, France is expected to see substantial growth in radiopharmaceutical development, cyclotron capacity expansion, and hybrid imaging technologies (PET/CT and SPECT/CT systems). France's position as a European leader in nuclear medicine is reinforced by its research institutions, pharmaceutical partnerships, and reimbursement policies that favor advanced diagnostic and therapeutic modalities.
  • The market's trajectory reflects both clinical demand and strategic investments in nuclear medicine infrastructure throughout the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 16.1% CAGR
  • Market Size, 2025 ~USD 413.8 Million
  • Forecast, 2030 ~USD 873.6 Million
  • Country France

France Nuclear Medicine Market Overview

Strong Market Growth :

France's nuclear medicine market is expanding at 16.1% CAGR, significantly outpacing the global rate of 15.1%, demonstrating exceptional market momentum and investment potential in the country.

Advanced Healthcare Infrastructure :

France's sophisticated healthcare system and high adoption rates of diagnostic imaging technologies create a favorable environment for nuclear medicine expansion and innovation.

Therapeutic Expansion :

Increasing adoption of therapeutic nuclear medicine procedures alongside diagnostic applications is driving market diversification and revenue growth across French healthcare institutions.

Market Valuation Trajectory :

The market is valued at $413.8 million in 2025 and projected to more than double to $873.6 million by 2030, representing substantial investment opportunities in France's nuclear medicine sector.

France Nuclear Medicine Market Dynamics

  • The country's robust regulatory framework and established reimbursement pathways support market expansion.
  • Healthcare providers are increasingly investing in nuclear medicine capabilities to enhance patient outcomes and operational efficiency.
  • Collaborations between research institutions and private healthcare providers are accelerating innovation and market penetration across France's regions..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • France's nuclear medicine market will nearly double from $413.8M (2025) to $873.6M (2030), driven by 16.1% CAGR growth.
    • France's aging demographic and rising chronic disease prevalence are accelerating demand for diagnostic and therapeutic nuclear medicine procedures.
    • France's advanced healthcare infrastructure and favorable reimbursement policies position it as a European nuclear medicine leader.
    • Radiopharmaceutical innovation and hybrid imaging technology expansion will be key growth catalysts for France's market through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    France Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES30.535.240.646.954.162.471.982.815.3
    DIAGNOSTIC & IMAGING CENTERS83.397.7114.7134.6158185.3217.3254.517.3
    HOSPITALS183.4212.4246.2285.3330.5382.7442.9511.815.8
    OTHER END USERS9.410.712.314.216.318.721.424.514.7
    TOTAL306.5356413.8481558.9649.2753.6873.616.1

    Target Audience

    • Medical Device Manufacturers : Evaluate market entry opportunities and expansion strategies in France's high-growth nuclear medicine sector with detailed sizing and growth projections.
    • Healthcare Investors & PE Firms : Assess investment potential in French nuclear medicine companies and healthcare infrastructure with quantified market growth and valuation trajectories.
    • Pharmaceutical & Radiopharmaceutical Companies : Identify market opportunities for diagnostic and therapeutic nuclear medicine products in France's expanding healthcare market with specific demand drivers.
    • Healthcare Consultants & Strategists : Support client advisory work with France-specific market intelligence, competitive analysis, and strategic recommendations for healthcare stakeholders.
    • Hospital & Imaging Center Operators : Understand market trends, investment requirements, and growth opportunities to optimize nuclear medicine service offerings and capital planning in France.

    Reasons to Buy this Report

    • Market-Specific Growth Intelligence : Gain detailed insights into France's 16.1% CAGR trajectory, enabling accurate forecasting and strategic planning tailored to the French nuclear medicine landscape.
    • Competitive Positioning Data : Understand France's outperformance versus global trends, identifying competitive advantages and market gaps for differentiation and market entry strategies.
    • Investment Decision Support : Access comprehensive valuation data ($413.8M to $873.6M) to support capital allocation decisions, M&A strategies, and expansion planning in France.
    • Regulatory & Reimbursement Insights : Understand France's healthcare infrastructure, reimbursement mechanisms, and regulatory environment specific to nuclear medicine adoption and commercialization.
    • Stakeholder-Specific Strategies : Develop targeted go-to-market strategies for French healthcare providers, payers, and patients based on country-specific market dynamics and adoption patterns.

    Frequently asked questions

    What is the projected size of France's nuclear medicine market by 2030?

    France's nuclear medicine market is projected to reach $873.6 million by 2030, up from $413.8 million in 2025, representing a 16.1% compound annual growth rate.

    What factors are driving growth in France's nuclear medicine market?

    France's market growth is driven by an aging population, rising chronic disease prevalence, advanced healthcare infrastructure, strong government investment, favorable reimbursement policies, and increasing adoption of diagnostic imaging and targeted radiotherapy solutions.

    Which applications are leading France's nuclear medicine market expansion?

    Oncology, cardiology, and neurology applications are leading France's nuclear medicine market expansion, supported by growing demand for PET/CT, SPECT/CT, and targeted radiotherapy procedures.

    How does France's nuclear medicine market compare to global trends?

    France's nuclear medicine market is growing at 16.1% CAGR, outpacing the global average of 15.1%, reflecting France's strong healthcare infrastructure and favorable market conditions.

    What technological innovations are shaping France's nuclear medicine sector?

    Radiopharmaceutical development, cyclotron capacity expansion, and hybrid imaging technologies (PET/CT and SPECT/CT systems) are key technological innovations driving France's nuclear medicine market growth through 2030.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status